Paper36934740
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
Loomba R and 11 others. Lancet Gastroenterol Hepatol, 2023. Cited by 468 papers, by iCite.
Cite this record
ConductScience Library. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Papers, record 36934740. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36934740
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
- PubMed
- Publication types
- Randomized Controlled Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus, Type 2 | Major topic |
| Non-alcoholic Fatty Liver Disease | Major topic |
| Adult | |
| Humans | |
| Male | |
| Female | |
| Middle Aged | |
| Glucagon-Like Peptide 1 | |
| Liver Cirrhosis | |
| Semaglutide |
Source PubMed
Grants10
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| U01 DK130190 | NIDDK NIH HHS | United States | U01DK130190 | PubMed and NIH | NIH RePORTER |
| UL1 TR001442 | NCATS NIH HHS | United States | UL1TR001442 | PubMed and NIH | NIH RePORTER |
| Department of Health | United Kingdom | PubMed | PubMed | ||
| P30 DK120515 | NIDDK NIH HHS | United States | P30DK120515 | PubMed and NIH | NIH RePORTER |
| U01 AA029019 | NIAAA NIH HHS | United States | U01AA029019 | PubMed and NIH | NIH RePORTER |
| R01 DK124318 | NIDDK NIH HHS | United States | R01DK124318 | PubMed and NIH | NIH RePORTER |
| U01 DK061734 | NIDDK NIH HHS | United States | U01DK061734 | PubMed and NIH | NIH RePORTER |
| P01 HL147835 | NHLBI NIH HHS | United States | P01HL147835 | PubMed and NIH | NIH RePORTER |
| R01 DK121378 | NIDDK NIH HHS | United States | R01DK121378 | PubMed and NIH | NIH RePORTER |
| R01 DK106419 | NIDDK NIH HHS | United States | R01DK106419 | PubMed and NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03987451 | A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage | Background | Yes |
Source ClinicalTrials.gov
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 36934739 | Semaglutide in NASH-related cirrhosis: too late to the party? | https://conductscience.org/library/papers/36934739 | PubMed |
| Comment in | 37453428 | Semaglutide in NASH-related cirrhosis: still a long way to go? | https://conductscience.org/library/papers/37453428 | PubMed |
References32
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33570776 | A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. | Hepatology | 2021 | https://conductscience.org/library/papers/33570776 | PubMed |
| 2 | 30144956 | EASL Clinical Practice Guidelines on nutrition in chronic liver disease. | J Hepatol | 2019 | https://conductscience.org/library/papers/30144956 | PubMed |
| 3 | 31309602 | Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease. | Hepatology | 2020 | https://conductscience.org/library/papers/31309602 | PubMed |
| 4 | 4950264 | Surgery and portal hypertension. | Major Probl Clin Surg | 1964 | https://conductscience.org/library/papers/4950264 | PubMed |
| 5 | 32027911 | Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. | Gastroenterology | 2020 | https://conductscience.org/library/papers/32027911 | PubMed |
| 6 | 34555346 | Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. | Lancet Gastroenterol Hepatol | 2021 | https://conductscience.org/library/papers/34555346 | PubMed |
| 7 | 34927277 | Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality. | Aliment Pharmacol Ther | 2022 | https://conductscience.org/library/papers/34927277 | PubMed |
| 8 | 30615985 | Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. | Diabetes Metab | 2019 | https://conductscience.org/library/papers/30615985 | PubMed |
| 9 | 28802062 | Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. | Hepatology | 2018 | https://conductscience.org/library/papers/28802062 | PubMed |
| 10 | 26608256 | Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. | Lancet | 2016 | https://conductscience.org/library/papers/26608256 | PubMed |
| 11 | 31537030 | Peculiarities of Cirrhosis due to Nonalcoholic Steatohepatitis (NASH). | Semin Liver Dis | 2020 | https://conductscience.org/library/papers/31537030 | PubMed |
| 12 | 33567185 | Once-Weekly Semaglutide in Adults with Overweight or Obesity. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33567185 | PubMed |
| 13 | 26047908 | Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. | J Hepatol | 2015 | https://conductscience.org/library/papers/26047908 | PubMed |
| 14 | 34822801 | Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. | Gastroenterology | 2022 | https://conductscience.org/library/papers/34822801 | PubMed |
| 15 | 30222962 | Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. | Gastroenterology | 2019 | https://conductscience.org/library/papers/30222962 | PubMed |
| 16 | 33989548 | Mechanisms and disease consequences of nonalcoholic fatty liver disease. | Cell | 2021 | https://conductscience.org/library/papers/33989548 | PubMed |
| 17 | 15915461 | Design and validation of a histological scoring system for nonalcoholic fatty liver disease. | Hepatology | 2005 | https://conductscience.org/library/papers/15915461 | PubMed |
| 18 | 33724511 | Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. | Hepatology | 2021 | https://conductscience.org/library/papers/33724511 | PubMed |
| 19 | 29990488 | Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. | Gastroenterology | 2018 | https://conductscience.org/library/papers/29990488 | PubMed |
| 20 | 27062661 | EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. | J Hepatol | 2016 | https://conductscience.org/library/papers/27062661 | PubMed |
Cited by292
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 468 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42942139 | Chronic Intermittent Hypoxia and MASLD in Obstructive Sleep Apnea: A Critical Appraisal of Mechanistic and Causal Evidence. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42942139 | PubMed |
| 42889937 | Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity. | Diabetes Obes Cardiometab CARE | 2026 | https://conductscience.org/library/papers/42889937 | PubMed |
| 42882002 | MetALD in Clinical Practice: Diagnosis, Non-Invasive Risk Stratification, and Management. | J Clin Med | 2026 | https://conductscience.org/library/papers/42882002 | PubMed |
| 42872191 | Metabolic dysfunction-associated steatotic liver disease assessment and management: Clinical practice guidance from the Canadian Association for the Study of the Liver. | Can Liver J | 2026 | https://conductscience.org/library/papers/42872191 | PubMed |
| 42862908 | Cardiovascular Complications of Chronic Liver Disease. | Circulation | 2026 | https://conductscience.org/library/papers/42862908 | PubMed |
| 42851902 | Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42851902 | PubMed |
| 42825923 | Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Diabetologia | 2026 | https://conductscience.org/library/papers/42825923 | PubMed |
| 42825265 | Semaglutide for MASH cirrhosis: a new therapeutic frontier or a false dawn? | eGastroenterology | 2026 | https://conductscience.org/library/papers/42825265 | PubMed |
| 42792628 | Pathogenesis-Informed Phenotype-Guided Therapy for MASH: A Three-Axis Translational Framework Within the MASLD Spectrum. | Biomedicines | 2026 | https://conductscience.org/library/papers/42792628 | PubMed |
| 42741872 | Low Steatosis May Signal Failing Reserve in Cirrhosis due to Metabolic Dysfunction-Associated Steatotic Liver Disease. | Liver Int | 2026 | https://conductscience.org/library/papers/42741872 | PubMed |
| 42737685 | The Effect of Prolyl Isomerase Pin1 on the Development of Metabolic Dysfunction-Associated Steatohepatitis and a New Treatment Strategy. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42737685 | PubMed |
| 42713454 | Glucagon-Like Peptide-1 Receptor Agonist Use Before and After Liver Transplant. | Gastroenterol Hepatol (N Y) | 2026 | https://conductscience.org/library/papers/42713454 | PubMed |
| 42712610 | Effects and safety of Huatan Qushi Huoxue granules on obesity-associated non-alcoholic fatty liver disease: a multicenter, randomized, double-blind, placebo-controlled trial. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42712610 | PubMed |
| 42697203 | Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis. | Cell Rep Med | 2026 | https://conductscience.org/library/papers/42697203 | PubMed |
| 42690550 | Emerging Topics In Obesity Treatment in the Setting of Organ Transplantation. | Curr Obes Rep | 2026 | https://conductscience.org/library/papers/42690550 | PubMed |
| 42687024 | Current therapeutic landscape and future treatment perspectives of MASH. | Nature | 2026 | https://conductscience.org/library/papers/42687024 | PubMed |
| 42683225 | Mechanobiological feedback loops and quantitative decision thresholds in organ fibrosis: Translational principles for antifibrotic therapy. | J Cell Commun Signal | 2026 | https://conductscience.org/library/papers/42683225 | PubMed |
| 42683000 | Bile acid-axis dysregulation in MASLD/MASH progression: from metabolic mismatch to inflammatory-fibrotic remodeling. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42683000 | PubMed |
| 42670691 | Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Treatment Strategies and Novel Therapies. | Gut Liver | 2026 | https://conductscience.org/library/papers/42670691 | PubMed |
| 42666665 | Mapping GLP-1 receptor agonist research across the MASLD-MASH-HCC continuum: a bibliometric and translational analysis. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42666665 | PubMed |
Genes9
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ADIPOQ | 9370 | PubTator's text mining | https://conductscience.org/library/genes/9370 | NCBI Gene |
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| GCG | 2641 | PubTator's text mining | https://conductscience.org/library/genes/2641 | NCBI Gene |
| GGT1 | 2678 | PubTator's text mining | https://conductscience.org/library/genes/2678 | NCBI Gene |
| GGTLC5P | 653590 | PubTator's text mining | https://conductscience.org/library/genes/653590 | NCBI Gene |
| GLP1R | 2740 | PubTator's text mining | https://conductscience.org/library/genes/2740 | NCBI Gene |
| GPT | 2875 | PubTator's text mining | https://conductscience.org/library/genes/2875 | NCBI Gene |
| SLC17A5 | 26503 | PubTator's text mining | https://conductscience.org/library/genes/26503 | NCBI Gene |
| TIMP1 | 7076 | PubTator's text mining | https://conductscience.org/library/genes/7076 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36934740
GET https://conductscience.org/api/papers/v1/36934740/references?page=2